Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Pharmaceutical industry paymen...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

Show other versions (1)
Bibliographic Details
Main Authors: Piotr Ozieranski, Eszter Saghy, Shai Mulinari
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619808/?tool=EBI
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619808/?tool=EBI

Similar Items

  • Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.
    by: Piotr Ozieranski, et al.
    Published: (2023-01-01)
  • Drug company payments to General Practices in England: Cross-sectional and social network analysis.
    by: Eszter Saghy, et al.
    Published: (2021-01-01)
  • Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
    by: Piotr Ozieranski, et al.
    Published: (2020-09-01)
  • International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
    by: Piotr Ozieranski, et al.
    Published: (2023-03-01)
  • Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
    by: Piotr Ozieranski, et al.
    Published: (2021-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs